• Respiree

  Led · Series A · Jul 2026

  Respiree develops a monitoring platform called 1Bio™ that integrates FDA‑cleared wearable sensors, artificial intelligence, and electronic health record connectivity to track the condition of patients with cardio‑respiratory diseases. Its system is designed to identify early signs of clinical deterioration to enable clinicians to intervene before critical events occur, with deployments reported in both hospital and home care settings. The company says its technology contributes to reducing hospital admissions and ICU transfers. Respiree is based at the Texas Medical Center Innovation campus in Houston and benefits from the TMC HealthTech Accelerator’s clinical, regulatory, and market-access support. Current company plans, supported by the Series A proceeds, focus on U.S. commercial expansion, strengthening the Houston headquarters, and advancing the proprietary platform’s development.

• DeepUll

  Participated · Series C · Apr 2025

  deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.

• Oxford Cancer Analytics

  Led · Series A · Jan 2025

  Oxford Cancer Analytics (OXcan) is a medtech company developing protein-based blood tests for early cancer detection using advanced proteomics, explainable machine learning, and AI. Its core product is a protein-based liquid biopsy intended to identify molecular signatures in high-risk lung cancer patients with high accuracy and localization capacity. OXcan leverages a diverse global biobank and, since 2023, has partnered with over 20 healthcare centers across three continents to develop and deploy its technology. The company has achieved ISO13485 certification and describes the test as affordable, minimally invasive, and suitable for routine population screening. OXcan plans to use new funding to develop and globally commercialize its next-generation lung cancer blood tests. It recently raised US$11 million in a Series A and appointed Dr. Heinrich Roder as Senior Vice President of R&D to advance its lung cancer blood test toward deployment.

• Proton

  Participated · Seed · Dec 2024

  Proton is developing a small device designed to be inserted just below the skin to continuously monitor potassium levels and pair with a smartphone app for patient alerts. A clinician dashboard is planned so care teams can view potassium trends and fine-tune therapies, potentially reducing in-clinic potassium testing, time, and costs. The company targets patients with chronic kidney disease and those at risk of heart failure, where potassium imbalances can be life‑threatening. Clinical trials are underway for the product, which Proton says is due to launch in 2025. The founders are CEO Sahan Ranamukhaarachchi (based in Vancouver) and CSO Victor Cadarso (based in Melbourne); the company has a commercial HQ in Canada and an R&D subsidiary in Melbourne, Australia. Proton positions its approach against other emerging potassium-monitoring firms and claims greater scalability, usability, and clinical impact.

• GraphAI

  Participated · Series A · Oct 2024

  GraphAI builds enterprise AI data infrastructure and operates the Akasic platform, which covers data connection, collection, transformation, AI inference, and agentic AI execution environments. The company is engaged in partnerships and proofs-of-concept with large customers in the financial and telecommunications sectors. GraphAI recently closed a $12 million Series A, bringing total funding to 20.6 billion won (about $14.7 million). It plans to use the new funding to introduce new product lines, expand into global markets, and strengthen its core R&D team. No revenue or user metrics were disclosed in the provided article.

No current team members are available.